Please assess the completion status of the following clinical trial:

Trial Title: Autologous Stem Cell Transplantation of Cells Engineered to Express Alpha-Galactosidase A in Patients With Fabry Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Male patients 18-50 years of age at the time of enrollment~2. Diagnosis of Fabry disease (FD) as defined by very low or absent α-gal A activity~3. Classic FD Type I phenotype with alpha-galactosidase A (GLA) genotyping~4. Patients on enzyme replacement therapy (ERT) prior to enrollment~5. Eastern Cooperative Oncology Group (ECOG) Performance status of 0 or 1~6. Adequate organ function within 21 days prior to Pre-Treatment Phase:~7. Willing and capable of signing and giving written informed consent in accordance with Research Ethics Board (REB) requirements~8. Willing to comply with all procedures outlined in the study protocol, cooperative with the protocol schedule, able to return for safety evaluation, or otherwise likely to complete the study~9. Willing to abstain from sexual activity or willing to use condoms during sexual intercourse from day of Melphalan administration on day -1 of Phase 3 until after 12 months follow-up post-transplant.~10. Willing to not donate sperm after receiving Melphalan. Sperm banking will be recommended to any patient who would like to father children in the future.~Exclusion Criteria:~1. Males with variant Fabry Disease.~2. Female gender~3. Use of immunosuppressive agents or any anticoagulant~4. Ongoing ERT-related infusion associated reactions of moderate-to-severe intensity~5. Presence of anti-agalsidase immunoglobulin (Ig)G antibodies above a threshold (5-fold above normal;) or evidence of high titre neutralizing antibodies~6. Blood test positive for Hepatitis B virus (HBV), Hepatitis C virus (HCV), human immunodeficiency virus (HIV), human T-cell lymphotropic virus type 1 (HTLV-1), human T-cell lymphotropic virus type 1 (HTLV-2), or Venereal Disease Research Laboratory test (VDRL; Transmissible Disease (TD) testing will be done in Pre-Treatment Phase 2 - see section 5.1 for full panel of TD tests. Patients will only be excluded from the study if positive for the TD tests listed here in this exclusion).~7. Uncontrolled bacterial, viral, or fungal infections~8. Prior malignancies except resected basal cell carcinoma~9. Chronic Kidney Disease (CKD) stage \>2~10. History of heart failure or left ventricle ejection fraction (LVEF) \<45% or moderate to severe diastolic dysfunction by standard criteria~11. Arrhythmia: bundle branch block, heart block degree II or III, atrial fibrillation, supraventricular tachycardia, ventricular tachycardia, ventricular fibrillation, cardiac arrest, pacemaker, implantable cardiac defibrillator~12. Coronary artery disease with angina, prior myocardial infarction, percutaneous transluminal coronary angioplasty with or without stent, coronary artery bypass graft surgery, moderate to severe valvular heart disease, valve replacement surgery~13. Uncontrolled hypertension~14. Diabetes mellitus~15. Advanced liver disease, liver failure, cirrhosis~16. Immune deficiency state~17. Moderate-to-severe chronic obstructive pulmonary disease (COPD)~18. Any hematological condition with white blood cells (WBC) \<3.0 x109/L, platelet count \<100 x109/L, and/or hemoglobin \<100 g/L~19. Prior bone marrow transplant (BMT) or organ transplant~20. Any condition that would preclude use of Melphalan~21. Use of a drug with cytotoxic or immunosuppressive effect within 60 days of trial entry~22. Uncontrolled psychiatric disorder~23. Active chronic infection~24. Prior tuberculosis~25. Any other serious concurrent disease~26. Cognitive impairment that would prevent informed consent~27. Use of an investigational drug within 30 days of stem cell transplant (SCT)

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Treatment Arm (Type: EXPERIMENTAL): Patients will receive Health Canada approved transduced autologous CD34+ cell product.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete